ABBV AbbVie Inc.

286.20USD+0.96%Mkt Cap: 505.89B USDP/E: 49.18

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimm…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap505.89B USD
Enterprise Value571.78B USD
Revenue (TTM)66.01B USD
Gross Profit42.96B USD
Net Income (TTM)4.23B USD
Revenue/Share37.32 USD
Last Price286.20 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees57.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)49.18
P/E (Forward)17.65
PEG0.58
EV/EBITDA17.95
EV/Revenue8.66
P/S7.66
P/B-110.37
EPS (TTM)5.82 USD
EPS (Forward)16.22 USD
52W Range
190.7585% of range302.93
52W High302.93 USD
52W Low190.75 USD
Profitability
Gross Margin70.24%
Oper. Margin36.63%
EBITDA Margin48.25%
Profit Margin6.91%
ROE-129.24%
ROA3.15%
ROIC21.85%
ROCE22.16%
Growth
Revenue Growth10.30%
Earnings Growth2282.10%
Cash Flow & Leverage
Operating CF19.03B USD
CapEx (TTM)1.21B USD
FCF Margin26.80%
FCF Yield3.50%
Net Debt70.54B USD
Net Debt/EBITDA2.21
Net Debt/FCF3.99
Balance Sheet
Debt/Equity-20.64
Current Ratio0.87
Quick Ratio0.56
Book Value/Sh-2.59 USD
Cash/Share6.09 USD
Dividends
Fwd Div Rate6.92 USD
Trail. Div Rate6.92 USD
Div. Yield2.44%
5Y Avg Yield3.39%
Payout Ratio117.35%
Ex-Div DateJan 15, 2027
Pay DateFeb 16, 2027
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)315.88 USD
Upside (mean)+10.4%
Target Range237.00 USD – 350.00 USD
237.00+10.4% to mean350.00
# Analysts26
Ownership
Shares Out.1.77B
Float1.76B
Insiders0.19%
Institutions77.59%
Short Interest
Short Ratio3.0d
Short % Float0.99%
Short % Out.0.89%
Shares Short15.81M
Short (prev mo.)16.28M
Technical
SMA 50277.85 (+3.0%)
SMA 200241.78 (+18.4%)
Beta0.19
S&P 52W Chg12.00%
Avg Vol (30d)4.81M
Avg Vol (10d)4.80M
Technical Indicators
RSI (14)49.2
MACD2.4987
MACD Signal4.2509
MACD Hist.-1.7521
BB Upper298.43 USD
BB Middle290.44 USD
BB Lower282.46 USD
BB Width5.50%
ATR (14)6.698 USD
Vol Ratio (20d)1.85x

About AbbVie (NYSE: ABBV)

›

AbbVie (NYSE: ABBV) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 57,000 employees.

The shares were at 286.20 USD on 20 November 2026, up 32.7% over 52 weeks. Its 52-week range is 190.75 USD to 302.93 USD: the price is 5.5% below the high and 50.0% above the low.

At a market capitalisation of 505.89B USD, it trades at 49.2 times trailing earnings and 17.6 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.3, a premium of 95% for ABBV. It pays a dividend yielding 2.44% (it pays out 117% of its earnings), against a median of 2.65% among the dividend payers in that peer group.

AbbVie reports return on equity of -129.2%, an operating margin of 36.6% and revenue up 10.3% year over year.

Its debt exceeds its cash by 70.54B USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 315.88 USD is 10.4% above the current price. The next earnings report is expected on 3 February 2027.